Filing excerpt
Defense and enforcement of our intellectual property rights is expensive and time consuming, even if the outcome is favorable to us.
sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htmRead the full source
Regeneron10-K: Major contract loss
Company faces significant operational and financial pain from expensive, time-consuming IP litigation.
What happened
Regeneron explicitly states that defending its intellectual property is costly and lengthy, representing a significant drain on resources and a potential risk to profitability. This creates a need for solutions that can optimize legal operations, manage IP portfolios, and mitigate litigation risk.
Source
Other signals in this filing (4)
- Cost reductionLibtayo royalty rate to Bristol-Myers Squibb drops from 8.0% to 2.5% from 2024-2026.Cost reduction
- Competitor namedRegeneron identifies cost-effective biosimilars as a primary risk to commercial success.Competitor named
- Litigation materialFacing patent infringement proceedings and review petitions for key drug EYLEA.Litigation material
- Joint ventureLibtayo royalty rate paid to Bristol-Myers Squibb drops from 8% to 2.5% as of Jan 2024.Joint venture
Extracted by Autobound
From the Signal API record- Signal
- 10-K: Major contract loss
What this signalsFilings often name leadership changes, deals and spending plans.
- Period
- FY2025
- Fiscal year end
- 12/31
- Filed
- Feb 4, 2026
More from Regeneron
- PatentsRegeneron Pharmaceuticals, Inc's patent output is steady: 168 grants in the past year, 15 in the past 30 days.Patents
- EarningsRegeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026Earnings
- RedditA Clinical Research Coordinator who completed two studies with Regeneron praised the company for having a super responsive, accessible, and cooperative team.Reddit
- In developmentParoxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market GrowthIn development
- GlassdoorEmployees report toxic work life balance and long hours despite good benefitsGlassdoor
- LaunchRegeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOPLaunch
More 10-K signals at other companies
- SEC 10-KAdvanced Biomed Inc.Advanced Biomed files for 10-K extension due to incomplete financial audit.SEC 10-K
- SEC 10-KBiomerica, Inc.Biomerica Appoints New Principal Financial Officer Xiaoxuan Qu Effective August 2026SEC 10-K
- SEC 10-KCleanCore Solutions, Inc.Pivoting to AI data centers with $100M in new funding for Minnesota projectSEC 10-K
The full record
From the Signal API recordDetails
- CIK
- 872589
- Accession number
- 0000872589-26-000008
- Filing year
- 2026
- Why it matters
- Urgency to improve
- Signal category
- Revenue
Extraction
- Confidence
- Medium
- Relevance
- 70%
- Sentiment
- Negative
- Detected
- Feb 10, 2026
- signal_type
sec-10k- signal_subtype
majorContractLoss
Use this data
Get every 10-K signal for Regeneron and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
Send it to your own tools
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/c3dc3d67-1b57-4b4d-8575-c9617332184d returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "c3dc3d67-1b57-4b4d-8575-c9617332184d",
"signal_type": "sec-10k",
"signal_subtype": "majorContractLoss",
"detected_at": "2026-02-10T07:49:34.287+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "Regeneron explicitly states that defending its intellectual property is costly and lengthy, representing a significant drain on resources and a potential risk to profitability. This creates a need for solutions that can optimize legal operations, manage IP portfolios, and mitigate litigation risk.",
"summary": "Company faces significant operational and financial pain from expensive, time-consuming IP litigation.",
"excerpts": "Defense and enforcement of our intellectual property rights is expensive and time consuming, even if the outcome is favorable to us.",
"relevance": 0.7,
"sentiment": "negative",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm",
"filing_date": "2026-02-04",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Urgency to improve",
"signal_category": "revenue"
}
}
curl https://signals.autobound.ai/v1/signals/c3dc3d67-1b57-4b4d-8575-c9617332184d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.